{
  "main_header": {
    "sid": 10039467,
    "name": "Suraksha Diagno.",
    "stock_name": "Suraksha Diagno.",
    "full_name": "Suraksha Diagnostic Ltd",
    "name_url": "stocks-analysis/suraksha-diagno",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "286.00",
    "chg": 15.9,
    "chgp": "5.89%",
    "dir": 1,
    "prev_price": "270.10",
    "mcapval": "1,463.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 544293,
    "symbol": "SURAKSHA",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE877V01027",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "34.0 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/suraksha-diagno-10039467-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Suraksha Diagno. Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/suraksha-diagno-upgraded-from-sell-to-hold-by-marketsmojo-on-11-aug-2025-3736848",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SurakshaDiagno_mojoScore_3736848.png",
        "date": "2025-11-29 17:52:21",
        "description": "Suraksha Diagno., a small-cap player in the Healthcare Services sector, has recently undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical positioning amid a challenging market environment."
      },
      {
        "title": "Why is Suraksha Diagno. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-suraksha-diagno-fallingrising-3730060",
        "imagepath": "",
        "date": "2025-11-26 01:33:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Suraksha Diagnostic’s shares have experienced a notable decline in recent trading sessions, with the stock falling by 3.27% over the last week and 5.60% in the past month. This contrasts sharply with the Sensex, which has recorded modest gains of 0.45% over the same one-month period and 8.25% year-to-date. The stock’s year-to-date performance is particularly concerning, with a steep decline of 22.10%, while the Sensex has advanced by over 8%. This divergence highlights the stock’s relative weakness amid a generally positive market environment.</p>\n<p>Adding to the negative momentum, Suraksha Diagnostic has underperformed its sector by 0.57% on the day, signalling that the stock is facing sector-specific headwinds or investor reserva..."
      },
      {
        "title": "Are Suraksha Diagno. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-suraksha-diagno-latest-results-good-or-bad-3690601",
        "imagepath": "",
        "date": "2025-11-11 19:44:38",
        "description": "Suraksha Diagnostic's latest financial results for Q2 FY26 present a mixed operational landscape. The company reported net sales of ₹78.73 crores, reflecting a year-on-year growth of 17.95% and a quarter-on-quarter increase of 8.46%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand for its diagnostic services. However, the operational efficiency appears to be under pressure, as evidenced by a decline in net profit to ₹8.99 crores, which represents a year-on-year decrease of 13.06% and a quarter-on-quarter drop of 4.36%.\n\nThe operating margin has contracted significantly, falling to 30.62% from 34.74% in the same quarter last year, indicating a decline of 412 basis points. Similarly, the profit after tax (PAT) margin has decreased to 11.22%, down 400 basis points year-on-year. These margin compressions raise concerns about the sustainability of the company's growth model..."
      },
      {
        "title": "Suraksha Diagnostic Q2 FY26: Margin Pressure Overshadows Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/suraksha-diagnostic-q2-fy26-margin-pressure-overshadows-revenue-growth-3686869",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SurakshaDiagnos_quaterlyResult_3686869.png",
        "date": "2025-11-10 19:37:16",
        "description": "Suraksha Diagnostic Limited, a Kolkata-based healthcare diagnostics provider with a market capitalisation of ₹1,669 crores, reported consolidated net profit of ₹8.99 crores for Q2 FY26, declining 4.36% quarter-on-quarter and 13.06% year-on-year. Despite robust revenue growth of 17.95% YoY to ₹78.73 crores, the company witnessed significant margin compression as operating profit margin (excluding other income) contracted to 30.62% from 34.74% in the year-ago quarter. The stock traded at ₹323.90 on November 10, 2025, showing resilience with gains of 10.66% over the past month, though it remains 13.76% lower year-to-date."
      }
    ],
    "total": 86,
    "sid": "10039467",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/suraksha-diagnostic-10039467"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "29-Jan-2026",
      "details": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that there will be a Conference Call viz. Earnings Call for the Analyst(s)/ Investor(s) on Friday 06 February 2026 at 2.30 pm (IST)",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for The Board Meeting To Be Held On Thursday 05 February 2026",
      "datetime": "27-Jan-2026",
      "details": "Suraksha Diagnostic Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday 05 February 2026 at the registered office of the Company to inter-alia consider and approve the unaudited (standalone and consolidated) financial results of the Company for the quarter and nine months ended 31 December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Change In Name Of Statutory Auditor Of The Company Pursuant To Conversion Into LLP",
      "datetime": "16-Jan-2026",
      "details": "The Statutory Auditor of the Company informed the Company about the change in the name of the audit firm from M S K A & Associates to M S K A & Associates LLP pursuant to conversion into a Limited Liability Partnership under the provisions of the Limited Liability Partnership Act 2008",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Suraksha Diagno. Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-11-29 17:52:21

Suraksha Diagno., a small-cap player in the Healthcare Services sector, has recently undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical positioning amid a challenging market environment.

Read More

Why is Suraksha Diagno. falling/rising?

2025-11-26 01:33:32

Recent Price Movement and Market Comparison Suraksha Diagnostic’s shares have experienced a notable decline in recent trading sessions, with the stock falling by 3.27% over the last week and 5.60% in the past month. This contrasts sharply with the Sensex, which has recorded modest gains of 0.45% over the same one-month period and 8.25% year-to-date. The stock’s year-to-date performance is particularly concerning, with a steep decline of 22.10%, while the Sensex has advanced by over 8%. This divergence highlights the stock’s relative weakness amid a generally positive market environment. Adding to the negative momentum, Suraksha Diagnostic has underperformed its sector by 0.57% on the day, signalling that the stock is facing sector-specific headwinds or investor reserva...

Read More

Are Suraksha Diagno. latest results good or bad?

2025-11-11 19:44:38

Suraksha Diagnostic's latest financial results for Q2 FY26 present a mixed operational landscape. The company reported net sales of ₹78.73 crores, reflecting a year-on-year growth of 17.95% and a quarter-on-quarter increase of 8.46%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand for its diagnostic services. However, the operational efficiency appears to be under pressure, as evidenced by a decline in net profit to ₹8.99 crores, which represents a year-on-year decrease of 13.06% and a quarter-on-quarter drop of 4.36%. The operating margin has contracted significantly, falling to 30.62% from 34.74% in the same quarter last year, indicating a decline of 412 basis points. Similarly, the profit after tax (PAT) margin has decreased to 11.22%, down 400 basis points year-on-year. These margin compressions raise concerns about the sustainability of the company's growth model...

Read More

Suraksha Diagnostic Q2 FY26: Margin Pressure Overshadows Revenue Growth

2025-11-10 19:37:16

Suraksha Diagnostic Limited, a Kolkata-based healthcare diagnostics provider with a market capitalisation of ₹1,669 crores, reported consolidated net profit of ₹8.99 crores for Q2 FY26, declining 4.36% quarter-on-quarter and 13.06% year-on-year. Despite robust revenue growth of 17.95% YoY to ₹78.73 crores, the company witnessed significant margin compression as operating profit margin (excluding other income) contracted to 30.62% from 34.74% in the year-ago quarter. The stock traded at ₹323.90 on November 10, 2025, showing resilience with gains of 10.66% over the past month, though it remains 13.76% lower year-to-date.

Read More

View All News